Unilife Corp. MedPro Prefilled Syringe

MedPro and Unilife Featured in Drug Development & Delivery Magazine

1 Minute Read

MedPro Safety Products, Inc. (MPSP-OTC.BB) and Unilife Corporation (UNIS-NASDAQ) were featured in the May 2012 edition of Drug Development & Delivery in an article, entitled "Prefilled Syringes - A Container of Choice for Pharma." Drug Development & Delivery interviewed leading players in the prefilled syringe market to learn about their products and how each company is addressing pharma’s needs for safety, ease of use, cost, and product differentiation. 

The full issue is available online at Drug Development & Delivery, May 2012. MedPro and Unilife are profiled on pages 38-40.

drug development and delivery may 2012

London-based business information company Visiongain expects the global prefilled syringe market to reach $3.9 billion in 2015 (up from $2.7 billion in 2012), fueled by improved performance, product stability, convenience of use, and cost-effectiveness.

MedPro Safety Products, Inc. (MPSP-OTC.BB) 

MedPro develops safer medication delivery and blood collection systems. The company licenses, develops, and manufactures transformational technologies, which are then marketed through global medical device partners. MedPro’s products address multiple product categories within the medication delivery and blood collection markets. Unlike many competitive products available on the market, MedPro’s products incorporate safety features that operate without user activation, and therefore require little or no clinician training to use. Visit www.medprosafety.com or http://www.crystalra.com/research-library/medpro-safety/ for additional information about MedPro and its product portfolio.

Unilife Corporation (UNIS-NASDAQ)

Unilife is a developer and commercial supplier of advanced drug delivery systems. The company reports that its Unifill syringe is the world's first and only prefilled syringe with fully integrated safety features. In addition to prefilled and hypodermic safety syringes with automatic, user-controlled needle retraction, Unilife has other proprietary technology platforms, including drug reconstitution delivery systems, auto-injectors, auto-infusion pump systems, and specialized devices for targeted organ delivery. Visit www.unilife.com or http://www.crystalra.com/research-library/unilife-corporation/ for greater details about Unilife and its various advanced drug delivery systems.

About Drug Development & Delivery

Drug Development & Delivery presents the latest scientific and business information in drug development for professionals working in Research & Development, Business Development, Product Life-Cycle Management, and Corporate Management. The magazine has approximately 20,000 subscribers.